Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs, harbor an amino acid substitution from lysine (K) to methionine (M) at position 27 of histone 3 variant 3 (H3.3). From a CD8+ T cell clone established by stimulation of HLA-A2+ CD8+ T cells with synthetic peptide encompassing the H3.3K27M mutation, complementary DNA for T cell receptor (TCR) &agr;- and &bgr;-chains were cloned into a retroviral vector. TCR-transduced HLA-A2+ T cells efficiently killed HLA-A2+H3.3K27M+ glioma cells in an antigen- and HLA-specific manner. Adoptive transfer of TCR-transduced T cells significantly suppressed the progression of glioma xenografts in mice. Alanine-scanning assays suggested the absence of known human proteins sharing the key amino acid residues required for recognition by the TCR, suggesting that the TCR could be safely used in patients. These data provide us with a strong basis for developing T cell–based therapy targeting this shared neoepitope.

[1]  Michael Platten,et al.  K27M-mutant histone-3 as a novel target for glioma immunotherapy , 2017, Oncoimmunology.

[2]  D. Ellison,et al.  Molecular pathology of paediatric central nervous system tumours , 2017, The Journal of pathology.

[3]  J. Barnholtz-Sloan,et al.  Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010 , 2016, Neuro-oncology.

[4]  S. Lageman,et al.  National Institute of Neurological Disorders and Stroke , 2017 .

[5]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[6]  Arie Perry,et al.  Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.

[7]  Liang Cheng,et al.  The 2016 World Health Organization classification of tumors of the urinary system and male genital organs: implications for the urologist , 2016 .

[8]  F. Furnari,et al.  Epidermal growth factor receptor targeting and challenges in glioblastoma. , 2016, Neuro-oncology.

[9]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[10]  N. Ahmed,et al.  Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. , 2016, Biochemical Society transactions.

[11]  W. Wels,et al.  Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival , 2016, Oncoimmunology.

[12]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[13]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[14]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[15]  L. Jensen,et al.  Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.

[16]  Simon C Watkins,et al.  STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[17]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[18]  S. Stevanović,et al.  A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.

[19]  Mark M. Davis,et al.  Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.

[20]  O. Becher,et al.  Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology , 2014, Pediatric Research.

[21]  C. June,et al.  Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts , 2013, Journal of Immunotherapy for Cancer.

[22]  Bent K Jakobsen,et al.  Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.

[23]  P. Wen,et al.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma , 2013, Expert review of vaccines.

[24]  R. Kebudi,et al.  Management of Diffuse Pontine Gliomas in Children: Recent Developments , 2013, Pediatric Drugs.

[25]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[26]  Clemencia Pinilla,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.

[27]  H. Ikeda,et al.  A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression , 2012, Molecular therapy. Nucleic acids.

[28]  B. Jakobsen,et al.  Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies , 2012, European journal of immunology.

[29]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[30]  R. Morgan,et al.  Genetic engineering with T cell receptors. , 2012, Advanced Drug Delivery Reviews.

[31]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[32]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[33]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Edward R. Kastenhuber,et al.  Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners , 2010, Cancer Immunology, Immunotherapy.

[35]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  R. Debets,et al.  T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. , 2010, Trends in molecular medicine.

[37]  H. Ikeda,et al.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. , 2009, Cancer research.

[38]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[39]  Edward R. Kastenhuber,et al.  Immunotherapeutic approaches for glioma. , 2009, Critical reviews in immunology.

[40]  Jian Huang,et al.  Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. , 2007, Cancer research.

[41]  Andrew K. Sewell,et al.  Human TCR-Binding Affinity is Governed by MHC Class Restriction1 , 2007, The Journal of Immunology.

[42]  Junichi Eguchi,et al.  Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models , 2007, Journal of Translational Medicine.

[43]  Jian Gang Zhang,et al.  Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics , 2007, Clinical Cancer Research.

[44]  I. Pollack,et al.  Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. , 2006, Cancer research.

[45]  S. Steinberg,et al.  Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.

[46]  I. Pollack,et al.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. , 2005, Neoplasia.

[47]  Paul Tempst,et al.  Histone Deimination Antagonizes Arginine Methylation , 2004, Cell.

[48]  M. A. van der Hoorn,et al.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. , 2003, Blood.

[49]  F. Marincola,et al.  Functional characterization of CTL against gp100 altered peptide ligands , 2003, Cancer Immunology, Immunotherapy.

[50]  I. Pollack,et al.  Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain , 2002 .

[51]  I. Pollack,et al.  Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  Y. Rivière,et al.  A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. , 2001, Journal of immunological methods.

[53]  M. Garcia-Peydró,et al.  Antagonism of Direct Alloreactivity of an HLA-B27-Specific CTL Clone by Altered Peptide Ligands of Its Natural Epitope1 , 2000, The Journal of Immunology.

[54]  C. Farina,et al.  Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.

[55]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[56]  M. Boeker,et al.  Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions , 1997, Allergy.

[57]  M. van de Weert,et al.  Identification of oxidized methionine in peptides. , 1996, Rapid communications in mass spectrometry : RCM.

[58]  C. Figdor,et al.  Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. , 1995, Cancer research.

[59]  D. Wiley,et al.  HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[61]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.